Aaron Weitzman

The growing fertility space is attracting substantial investments from both venture capital and private equity. Go deeper (1 min. read)

Pharma's need for efficient clinical trials has never been more stark amid FDA upheaval.

This week we delivered

NYC-based company connects caregivers to non-medical caregiving services.

Food-as-medicine is at a crossroads between likely federal funding cuts and increased focus on healthy lifestyle changes on the other

This week we brought you

The company says it is on track to become cash-flow positive by the first half of 2026.

A $70 million Series B comes during a turbulent time with possible federal cuts for such programs.

It's the highest quarterly investment in the space since the second quarter of 2022.

The company collected first-round bids this week.

The company operates under a shared revenue model with its health care provider customers.

Linden now has ample dry powder to pounce on a large backlog of PE-backed deals in health care.

This is the second RCM deal this week.

An ongoing technology arms race is reshaping revenue cycle management, as investors rush to capitalize on the clear ROI for health care players.

This marks the first merger in the OTC hearing aid market since the FDA established the regulatory category in 2022..

Nucleus, a whole-genome testing startup

The demise of 23andMe

Next Life Sciences is raising $20 million

Ex-Apple health leader joins Oura

Health Tech: Oura's first CMO